JP2010504352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504352A5 JP2010504352A5 JP2009529371A JP2009529371A JP2010504352A5 JP 2010504352 A5 JP2010504352 A5 JP 2010504352A5 JP 2009529371 A JP2009529371 A JP 2009529371A JP 2009529371 A JP2009529371 A JP 2009529371A JP 2010504352 A5 JP2010504352 A5 JP 2010504352A5
- Authority
- JP
- Japan
- Prior art keywords
- benzazepine
- phenyl
- oxospiro
- dihydro
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 46
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 28
- -1 2,3-dihydro-1′-methyl-2′-oxospiro {4H-1-benzazepine-4,3′-piperidine}- 1 (5H) -yl Chemical group 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 5
- 102000002852 Vasopressins Human genes 0.000 claims 5
- 108010004977 Vasopressins Proteins 0.000 claims 5
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 5
- 125000003003 spiro group Chemical group 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 5
- 229960003726 vasopressin Drugs 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000002536 vasopressin receptor antagonist Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- FLGYZVSYNLBJDV-UHFFFAOYSA-N 2-spiro[1-benzazepine-4,3'-pyrrolidine]-1'-ylacetic acid Chemical compound C1N(CC(=O)O)CCC21C=C1C=CC=CC1=NC=C2 FLGYZVSYNLBJDV-UHFFFAOYSA-N 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021036 Hyponatraemia Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 206010001488 Aggression Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000027601 Inner ear disease Diseases 0.000 claims 1
- 208000017119 Labyrinth disease Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 1
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- DIFPAMJXWONROD-UHFFFAOYSA-N spiro[1-benzazepine-4,3'-pyrrolidine] Chemical compound C1NCCC21C=C1C=CC=CC1=NC=C2 DIFPAMJXWONROD-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82667106P | 2006-09-22 | 2006-09-22 | |
| PCT/US2007/078926 WO2008036759A1 (en) | 2006-09-22 | 2007-09-19 | Spiro benzazepines as vasopressin antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504352A JP2010504352A (ja) | 2010-02-12 |
| JP2010504352A5 true JP2010504352A5 (enExample) | 2010-12-02 |
Family
ID=39093069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009529371A Pending JP2010504352A (ja) | 2006-09-22 | 2007-09-19 | バソプレッシン拮抗薬としてのスピロベンズアゼピン類 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7825111B2 (enExample) |
| EP (1) | EP2076517A1 (enExample) |
| JP (1) | JP2010504352A (enExample) |
| CN (1) | CN101541807A (enExample) |
| AU (1) | AU2007299822A1 (enExample) |
| CA (1) | CA2665851A1 (enExample) |
| WO (1) | WO2008036759A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ532033A (en) * | 2001-10-12 | 2006-11-30 | Azevan Pharmaceuticals Inc | 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists |
| EP1868434A4 (en) | 2005-03-22 | 2011-10-26 | Azevan Pharmaceuticals Inc | BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS |
| AR066834A1 (es) * | 2007-06-06 | 2009-09-16 | Janssen Pharmaceutica Nv | Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central. |
| ES2662350T3 (es) | 2010-07-01 | 2018-04-06 | Azevan Pharmaceuticals, Inc. | Procedimientos para el tratamiento del trastorno por estrés postraumático |
| ES2633981T3 (es) | 2012-12-26 | 2017-09-26 | Sanwa Kagaku Kenkyusho Co., Ltd | Nuevo derivado de benzoazepina y uso médico del mismo |
| TW201600522A (zh) * | 2014-02-20 | 2016-01-01 | 赫孚孟拉羅股份公司 | 螺－唑酮 |
| AU2015237253B2 (en) | 2014-03-28 | 2019-11-14 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating neurodegenerative diseases |
| JP7368357B2 (ja) * | 2017-09-05 | 2023-10-24 | ブラックソーン セラピューティクス インコーポレイテッド | バソプレシン受容体アンタゴニストならびにそれに関連する生成物および方法 |
| MY208313A (en) | 2017-09-15 | 2025-04-30 | Azevan Pharmaceuticals Inc | Compositions and methods for treating brain injury |
| WO2019141575A1 (de) | 2018-01-16 | 2019-07-25 | Bayer Aktiengesellschaft | Unterstützung bei der behandlung von herzinsuffizienz |
| CN109608411A (zh) * | 2018-12-17 | 2019-04-12 | 上海合全药物研发有限公司 | 一种叔丁基-1-氧亚基-6-氧杂-9-氮杂螺[4.5]癸烷-9-甲酸基酯的制法 |
| EP4192957A4 (en) * | 2020-08-07 | 2024-09-04 | Casma Therapeutics, Inc. | Trpml modulators |
| CN112939864B (zh) * | 2021-01-29 | 2022-05-06 | 中国医科大学 | 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617302A (en) | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
| JP2905909B2 (ja) * | 1991-04-19 | 1999-06-14 | 大塚製薬株式会社 | バソプレシン拮抗剤 |
| US5985869A (en) | 1989-10-20 | 1999-11-16 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| WO1991005549A1 (en) | 1989-10-20 | 1991-05-02 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds |
| US5258510A (en) | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| JPH08502474A (ja) | 1992-10-07 | 1996-03-19 | メルク エンド カンパニー インコーポレーテッド | トコリティックオキシトシンレセプターアンタゴニスト |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| FR2708606B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| AUPP150098A0 (en) | 1998-01-27 | 1998-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| HUP0301590A3 (en) * | 2000-07-05 | 2005-01-28 | Ortho Mcneil Pharm Inc | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists, pharmaceutical compositions containing them and their preparation |
| CA2432825A1 (en) * | 2000-12-15 | 2002-06-20 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
| US7011898B2 (en) * | 2003-03-21 | 2006-03-14 | Air Products And Chemicals, Inc. | Method of joining ITM materials using a partially or fully-transient liquid phase |
| EA200501829A1 (ru) | 2003-06-17 | 2006-06-30 | Янссен Фармацевтика Н. В. | Способ получения непептидных замещённых спиробензоазепиновых производных |
| ES2332724T3 (es) | 2003-06-17 | 2010-02-11 | Janssen Pharmaceutica Nv | Espirobenzoazepinas sustituidas. |
| JP2009523806A (ja) | 2006-01-20 | 2009-06-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物 |
-
2007
- 2007-09-19 AU AU2007299822A patent/AU2007299822A1/en not_active Abandoned
- 2007-09-19 EP EP07842807A patent/EP2076517A1/en not_active Withdrawn
- 2007-09-19 CN CNA2007800432304A patent/CN101541807A/zh active Pending
- 2007-09-19 JP JP2009529371A patent/JP2010504352A/ja active Pending
- 2007-09-19 CA CA002665851A patent/CA2665851A1/en not_active Abandoned
- 2007-09-19 US US11/857,954 patent/US7825111B2/en not_active Expired - Fee Related
- 2007-09-19 WO PCT/US2007/078926 patent/WO2008036759A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504351A5 (enExample) | ||
| AU2017283769B2 (en) | Compounds and compositions for inhibiting the activity of SHP2 | |
| ES2873895T3 (es) | Compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53 | |
| JP5132673B2 (ja) | ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール | |
| JP2023530320A (ja) | Ｎａｖ１．８阻害剤としての５－オキソピロリジン－３－カルボキサミド | |
| JP2019163287A (ja) | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 | |
| JP2019520398A5 (enExample) | ||
| CN112672997A (zh) | 哒嗪酮衍生物 | |
| BR112017016193B1 (pt) | Derivados de 4h-pirrolo[3,2-c]piridin-4-ona | |
| RU2003115490A (ru) | Амидные производные в качестве антагонистов nmda рецептора | |
| CN107108522B (zh) | 作为mIDH1抑制剂的苯并咪唑-2-胺 | |
| JP2008513498A5 (enExample) | ||
| JP2005508967A5 (enExample) | ||
| CN101605792A (zh) | 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途 | |
| KR20080007268A (ko) | ＨＣＶ 억제제로서 유용한 피리도[2,3-ｄ]피리미딘 및 그의제조 방법 | |
| JPWO2004113300A1 (ja) | 新規三環性複素環化合物 | |
| DK2303895T3 (en) | Thiazolyl AND OXAZOLYLISOQUINOLINONER AND methods of use thereof | |
| NZ225706A (en) | 2-((4-piperidyl)methyl)-1,2,3,4-tetrahydro-9h-pyrido(3,4-b) indole derivatives and their preparation | |
| JP6386527B2 (ja) | カリウムイオンチャネル阻害剤としてのピロロピリダジン | |
| JP2006523193A5 (enExample) | ||
| JP2017518348A (ja) | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 | |
| CN102482256B (zh) | N-取代的环状氨基衍生物 | |
| JP2022547777A (ja) | ヒダントイン誘導体 | |
| JP2016514129A (ja) | カリウムイオンチャネル阻害剤としてのフタラジン | |
| JP2004507527A5 (enExample) |